Literature DB >> 20977377

Restless legs syndrome and near-infrared light: An alternative treatment option.

Ulrike H Mitchell1, J William Myrer, A Wayne Johnson, Sterling C Hilton.   

Abstract

There are few treatment options in managing restless legs syndrome (RLS); the most frequently used are dopaminergic drugs and movement. New treatment options are highly sought after. This study evaluated the effectiveness of monochromatic near-infrared light treatment in decreasing symptoms associated with RLS. The design used was 2×6 repeated-measures design with two groups (treatment and control) and six repeated measures (baseline, weeks 1-4, and posttreatment). Data collection took place in the university modalities laboratory. Thirty-four volunteers with symptoms of RLS were randomly assigned to a treatment or control group. Over a 4-week period subjects underwent twelve 30-min treatments to their lower legs with near-infrared light. The International RLS rating scale (IRLS) was used to assess and track patient symptoms. There was a steady decrease in symptoms associated with RLS over the 4 weeks in the treatment group. After 4 weeks of treatment the treatment group had a significantly greater improvement in restless legs syndrome symptoms than the control group (p<0.001); improvement was still significant after 4 weeks posttreatment compared to baseline (p<0.001). Treatment with near-infrared light does decrease symptoms associated with RLS as demonstrated in lower IRLS scores. This new noninvasive method of treating RLS might become a valuable new management option. More research is needed to determine the mechanism(s) behind infrared light treatment and RLS.

Entities:  

Mesh:

Year:  2010        PMID: 20977377     DOI: 10.3109/09593985.2010.511440

Source DB:  PubMed          Journal:  Physiother Theory Pract        ISSN: 0959-3985            Impact factor:   2.279


  9 in total

1.  Decreased Symptoms without Augmented Skin Blood Flow in Subjects with RLS/WED after Vibration Treatment.

Authors:  Ulrike H Mitchell; Sterling C Hilton; Erik Hunsaker; Jan Ulfberg
Journal:  J Clin Sleep Med       Date:  2016-07-15       Impact factor: 4.062

Review 2.  Sleep disorders in chronic obstructive pulmonary disease: etiology, impact, and management.

Authors:  Rohit Budhiraja; Tauseef A Siddiqi; Stuart F Quan
Journal:  J Clin Sleep Med       Date:  2015-03-15       Impact factor: 4.062

3.  Effect of Near-Infrared Light Therapy Based on Acupoints on the Severity of Restless Legs Syndrome in Patients Undergoing Hemodialysis: A Single-Blind, Randomized Controlled Trial.

Authors:  Mohammad Mehdi Mohammadi; Ali Akbar Vaisi Raygani; Akram Ghobadi; Soheila Samadzadeh; Nader Salari
Journal:  Clin Med Res       Date:  2018-05-18

4.  Monochromatic Infrared Photo Energy Versus Low Level Laser Therapy in Chronic Low Back Pain.

Authors:  Tarek Abdel Rahman Ali Ammar
Journal:  J Lasers Med Sci       Date:  2015-10-27

Review 5.  Medical devices for restless legs syndrome - clinical utility of the Relaxis pad.

Authors:  Ulrike H Mitchell
Journal:  Ther Clin Risk Manag       Date:  2015-12-03       Impact factor: 2.423

Review 6.  Restless Legs Syndrome: Contemporary Diagnosis and Treatment.

Authors:  Thomas R Gossard; Lynn Marie Trotti; Aleksandar Videnovic; Erik K St Louis
Journal:  Neurotherapeutics       Date:  2021-04-20       Impact factor: 7.620

7.  Nondrug-related aspect of treating Ekbom disease, formerly known as restless legs syndrome.

Authors:  Ulrike H Mitchell
Journal:  Neuropsychiatr Dis Treat       Date:  2011-05-06       Impact factor: 2.570

8.  Peripheral Dopamine in Restless Legs Syndrome.

Authors:  Ulrike H Mitchell; J Daniel Obray; Erik Hunsaker; Brandon T Garcia; Travis J Clarke; Sandra Hope; Scott C Steffensen
Journal:  Front Neurol       Date:  2018-03-15       Impact factor: 4.003

9.  Pharmacologic Treatment of Restless Legs Syndrome.

Authors:  Qing Lv; Xinlin Wang; Tetsuya Asakawa; Xiao Ping Wang
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.